The quality and quantity of bone are crucial to the success of dental implant treatment. Recently, bone grafting materials have reached some limitations. This study aimed to evaluate the biocompatibility of novel drug delivery material, injectable methacrylated hyaluronic acid hydrogel incorporated with different ratios of mannitol and BSA (Man/BSA MeHA), to human alveolar bone cells. The three-dimensionally encapsulated cell culture was evaluated with the resazurin cell viability test, alkaline phosphatase activity assay, immunohistochemistry test for collagen type-I synthesis, and cell morphology. The results showed that the encapsulated cells were viable in all four ratios of Man/BSA MeHA hydrogel and the average metabolic rate was not less than the control group. The morphology test showed round shape cells at the upper portion of the hydrogel and fibroblast-like or polygonal shape at the lower portion of hydrogel next to the culture plate. All four groups could express enzyme alkaline phosphatase and collagen type-I. In conclusion, four ratios of Man/BSA MeHA hydrogel were biocompatible with primary human alveolar bone cells.

骨骼的质量和数量对于种植牙治疗的成功至关重要。近来，骨移植材料已达到一定的局限性。本研究旨在评估新型药物递送材料、可注射的甲基丙烯酸化透明质酸水凝胶与不同比例的甘露醇和牛血清白蛋白 (Man/BSA MeHA) 对人牙槽骨细胞的生物相容性。用刃天青细胞活力测试、碱性磷酸酶活性测定、I 型胶原合成的免疫组织化学测试和细胞形态对三维封装的细胞培养物进行评估。结果表明，包封的细胞在所有四种比例的Man/BSA MeHA水凝胶中均能存活，并且平均代谢率不低于对照组。形态学测试显示，水凝胶上部呈圆形细胞，靠近培养板的水凝胶下部呈成纤维细胞样或多边形。所有四个组都可以表达酶碱性磷酸酶和I型胶原蛋白。总之，四种比例的 Man/BSA MeHA 水凝胶与原代人牙槽骨细胞具有生物相容性。